Abstract Details

Title Patient Satisfaction With Ravulizumab Treatment for Generalized Myasthenia Gravis (gMG) in the United States (US)

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P11 - Poster Session 11 (11:45 AM-12:45 PM)

Poster/Presentation
Number 9-003

Objective To understand the real-world patient experience with ravulizumab, including health-related quality of life (HR-QoL) and other disease-related impacts, and to determine key drivers of the ravulizumab treatment experience using a patient satisfaction survey.

Background Anti-acetylcholine receptor antibody-positive (AChR-Ab+) gMG is a rare, chronic, autoimmune disease. Ravulizumab, a terminal complement component 5 inhibitor with maintenance dosing of once every 8 weeks (Q8W), is approved for the treatment of AChR-Ab+ gMG. Here, we present results of a patient satisfaction survey among US adults with gMG receiving ravulizumab.

Design/Methods

This cross-sectional, web-based survey, conducted from June–August 2025, was developed with input from patients and healthcare professionals. Participants were recruited from patient panels through a recruitment vendor partner and through US patient advisory groups. The survey assessed demographics/clinical characteristics, HR-QoL measures (eg, ability to socialize, function in a career, sleep, manage activities of daily living [ADL]), and treatment satisfaction.

Results The analysis included 124 respondents (female: 59%; mean±SD age: 47±13.3yrs; mean±SD Myasthenia Gravis ADL score: 6.5±4.3). Most respondents (73%) had received ravulizumab for ≥12mo; 55% initiated ravulizumab within 2yrs of diagnosis. Any improvement in ≥1 HR-QoL measure was reported in 96% of patients; significant improvement in ≥1 HR-QoL measure was reported in 75% of patients. Most frequently reported improvements were in the ability to socialize/maintain relationships (73%), the ability to function in a career (71%), real or perceived social isolation (71%), the ability to complete ADLs (70%), and the ability to participate in hobbies, leisure, or volunteering (70%). Respondents reported satisfaction with infusion frequency (79%), symptom relief (78%), HR-QoL improvements (76%), and their overall treatment experience (77%). Primary drivers of satisfaction included HR-QoL improvements (50%) and Q8W infusion frequency (23%).

Conclusions These results demonstrate that the majority of survey respondents with gMG receiving ravulizumab in the US were overall satisfied with ravulizumab and experienced meaningful HR-QoL improvements.

Authors/Disclosures
Chelsea Shugars, MD (UT Erlanger Neurology) PRESENTER	Dr. Shugars has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Natus. Dr. Shugars has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Shugars has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MTPA.
Brianna L. Poole, CCMA	Ms. Poole has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL Behring. Ms. Poole has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Ms. Poole has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion Pharmeceuticals.
Karen Yee, PhD (Alexion)	Dr. Yee has received personal compensation for serving as an employee of Alexion. Dr. Yee has stock in Alexion. Dr. Yee has stock in Takeda.
Jeffrey Yu, PhD (Alexion)	Dr. Yu has received personal compensation for serving as an employee of Alexion. Dr. Yu has stock in AstraZeneca.
Nicole Betor (Avalere)	Nicole Betor has received personal compensation for serving as an employee of Avalere Health.
Elizabeth Crevier, MPH	Mrs. Crevier has received personal compensation for serving as an employee of Avalere Health.
Christopher A. Scheiner, MD, PhD (TCNI)	Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Scheiner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals . Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL Behring . Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx Pharmaceuticals. Dr. Scheiner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jansssen. Dr. Scheiner has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for CSL Behring . Dr. Scheiner has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Alexion Pharmaceuticals . Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. The institution of Dr. Scheiner has received research support from Alexion Pharmaceuticals .

��ɫ��

��ɫ��